Regulatory collaboration is increasing at the global level. In the past two years the Brazilians and Chinese (two nations which like India have fought intellectual property battles with the west) are collaborating with western regulators and working out how to improve drug quality. Yet as more players come to the table to formulate policy for access to quality, safe and effective medicines, India continues to remain outside the fold.
A co-author on the paper is Dinesh Thakur who draws on his experience bringing to light the quality control failures at Ranbaxy, India’s most famous drug producer. The result of Thakur’s whistleblowing was a historic criminal case with Ranbaxy found guilty of seven felony counts, paying a $500 million fine. The impact on patients of Ranbaxy’s mendacity is simply unknown. Thakur joined me for a lively panel discussion on the subject at the American Enterprise Institute.
We also heard from Dr. Andreas Seiter, the World Bank’s leading pharmaceutical expert who acknowledge high levels of corruption in pharmaceutical production in emerging markets like India, and Dr. Harry Lever, a renowned cardiologist who discussed having to switch patients from generics back to brand medications due to poor responses.
You can watch a video of the full event here.